
Revolutionary Blood Test Seeks to Transform Early Cancer Detection
Aditxt’s subsidiary, Pearsanta, is planning an ambitious IPO with the support of Dominari Securities to advance global cancer diagnostics. Innovative MitomicĀ® Technology detects mitochondrial DNA deletions to enable early cancer detection through simple blood tests. Pearsanta’s approach aims to revolutionize medical diagnostics